SGN-LIV1A: A novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer

Molecular Cancer Therapeutics

Volumn 13, Issue 12, 2014, Pages 2991-3000

  Sussman, Django ^a   Smith, Leia M ^a   Anderson, Martha E ^a   Duniho, Steve ^a   Hunter, Joshua H ^a   Kostner, Heather ^a   Miyamoto, Jamie B ^a   Nesterova, Albina ^a   Westendorf, Lori ^a   Van Epps, Heather A ^a   Whiting, Nancy ^a   Benjamin, Dennis R ^a  

^a SEATTLE GENETICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SLC39A6; UNCLASSIFIED DRUG; VEDOTIN; ZINC TRANSPORTER; ZINC TRANSPORTER LIV 1; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CATION TRANSPORT PROTEIN; SGN-LIV1A; SLC39A6 PROTEIN, HUMAN; TUMOR PROTEIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST METASTASIS; BREAST TUMOR; CANCER IMMUNOTHERAPY; CLINICAL EVALUATION; COMPLEMENTARITY DETERMINING REGION; CONJUGATION; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY ASSAY; DNA FINGERPRINTING; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONAL THERAPY; HYDROPHOBIC INTERACTION CHROMATOGRAPHY; IMMORTALIZED CELL LINE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MCF 7 CELL LINE; MELANOMA; NONHUMAN; OVARY CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; SHORT TANDEM REPEAT; UTERINE CERVIX CANCER; UTERUS CANCER; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIBODY AFFINITY; BREAST NEOPLASMS; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOPHENOTYPING; LYSOSOME; METABOLISM; METASTASIS; MICROTUBULE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY AFFINITY; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CATION TRANSPORT PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOCONJUGATES; IMMUNOPHENOTYPING; LYSOSOMES; MCF-7 CELLS; MICROTUBULES; NEOPLASM METASTASIS; NEOPLASM PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84917740828     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0896     Document Type: Article

References (20)

1. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med 2013;64:15-29.
2. Taylor KM, Morgan HE, Johnson A, Hadley LJ, Nicholson RI. Structure-function analysis of LIV-1, the breast cancer-associated protein that belongs to a new subfamily of zinc transporters. Biochem J 2003;375:51-9.
3. Lopez V, Kelleher SL. Zip6-attenuation promotes epithelial-to-mesenchymal transition in ductal breast tumor (T47D) cells. Exp Cell Res 2010;316:366-75.
4. Manning DL, Daly RJ, Lord PG, Kelly KF, Green CD. Effects of oestrogen on the expression of a 4.4 kb mRNA in the ZR-75-1 human breast cancer cell line. Mol Cell Endocrinol 1988;59:205-12.
5. Yamashita S, Miyagi C, Fukada T, Kagara N, Che YS, Hirano T. Zinc transporter LIVI controls epithelial-mesenchymal transition in zebra-fish gastrula organizer. Nature 2004;429:298-302.
6. Lue HW, Yang X, Wang R, Qian W, Xu RZ, Lyles R, et al. LIV-1 promotes prostate cancer epithelial-to-mesenchymal transition and metastasis through HB-EGF shedding and EGFR-mediated ERK signaling. PLoS ONE 2011;6:e27720.
7. Zhao L, Chen W, Taylor KM, Cai B, Li X. LIV-1 suppression inhibits HeLa cell invasion by targeting ERK1/2-Snail/Slug pathway. Biochem Biophys Res Commun 2007;363:82-8.
8. Unno J, Satoh K, Hirota M, Kanno A, Hamada S, Ito H, et al. LIV-1 enhances the aggressive phenotype through the induction of epithelial to mesenchymal transition in human pancreatic carcinoma cells. Int J Oncol 2009;35:813-21.
9. Taylor KM, Hiscox S, Nicholson RI. Zinc transporter LIV-1: a link between cellular development and cancer progression. Trends Endocrinol Metab 2004;15:461-3.
10. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005;17:548-58.
11. Manning DL, Robertson JF, Ellis IO, Elston CW, McClelland RA, Gee JM, et al. Oestrogen-regulated genes in breast cancer: association of pLIV1 with lymph node involvement. Eur J Cancer 1994;30A:675-8.
12. Dressman MA, Walz TM, Lavedan C, Barnes L, Buchholtz S, Kwon I, et al. Genes that co-cluster with estrogen receptor alpha in microarray analysis of breast biopsies. Pharmacogenomics J 2001;1:135-41.
13. Tozlu S, Girault I, Vacher S, Vendrell J, Andrieu C, Spyratos F, et al. Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocr Relat Cancer 2006;13:1109-20.
14. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21:778-84.
15. Kabat EANational Institutes of Health (U.S.). Sequences of proteins of immunological interest. 5th ed. Bethesda, MD. Washington, DC: U.S. Dept. of Health and Human Services, Public Health Service For sale by U.S. G.P.O.; 1991.
16. Lyon RP, Meyer DL, Setter JR, Senter PD. Conjugation of anticancer drugs through endogenous monoclonal antibody cysteine residues. Methods Enzymol 2012;502:123-38.
17. Sharman JP, Oki Y, Advani RH, Bello CM, Winter JN, Yang Y, et al. A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: interim results in patients with DLBCL and other B-cell lymphomas, 2013. Presented at the 55th Annual Meeting and Exposition of the American Society of Hematology; December 7-10. 2013; New Orleans, LA.
18. Boghaert ER, Khandke K, Sridharan L, Armellino D, Dougher M, Dijoseph JF, et al. Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy. Int J Oncol 2006;28:675-84.
19. Kovtun YV, Audette CA, Ye Y, Xie H, Ruberti MF, Phinney SJ, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 2006;66:3214-21.
20. Howlader N, Noone A, Krapcho M, Garshell J, Neyman N, Altekruse S, et al. SEER cancer statistics review, 1975-2010. Bethesda, MD: National Cancer Institute; 2013.